Arcellx, Inc.

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, VRTX has a market cap of 115B. Regarding current trading prices, ACLX is priced at $115.07, while VRTX trades at $453.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas VRTX's P/E ratio is 26.91. In terms of profitability, ACLX's ROE is -0.55%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ACLX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check VRTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, REGN has a market cap of 74.2B. Regarding current trading prices, ACLX is priced at $115.07, while REGN trades at $721.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas REGN's P/E ratio is 17.58. In terms of profitability, ACLX's ROE is -0.55%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ACLX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check REGN's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ACLX is priced at $115.07, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ACLX's ROE is -0.55%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ACLX and VRNA have similar daily volatility (0.00).Check VRNA's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ARGX has a market cap of 49.7B. Regarding current trading prices, ACLX is priced at $115.07, while ARGX trades at $805.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ARGX's P/E ratio is 35.61. In terms of profitability, ACLX's ROE is -0.55%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ACLX is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ARGX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ACLX is priced at $115.07, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ACLX's ROE is -0.55%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ACLX is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check SGEN's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ALNY has a market cap of 38.9B. Regarding current trading prices, ACLX is priced at $115.07, while ALNY trades at $291.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ALNY's P/E ratio is 73.05. In terms of profitability, ACLX's ROE is -0.55%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ACLX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ALNY's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, RVMD has a market cap of 31.9B. Regarding current trading prices, ACLX is priced at $115.07, while RVMD trades at $149.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas RVMD's P/E ratio is -21.09. In terms of profitability, ACLX's ROE is -0.55%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ACLX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check RVMD's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, INSM has a market cap of 25.6B. Regarding current trading prices, ACLX is priced at $115.07, while INSM trades at $116.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas INSM's P/E ratio is -20.48. In terms of profitability, ACLX's ROE is -0.55%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ACLX and INSM have similar daily volatility (0.00).Check INSM's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, UTHR has a market cap of 24.6B. Regarding current trading prices, ACLX is priced at $115.07, while UTHR trades at $579.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas UTHR's P/E ratio is 21.42. In terms of profitability, ACLX's ROE is -0.55%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ACLX and UTHR have similar daily volatility (0.00).Check UTHR's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, ACLX is priced at $115.07, while BNTX trades at $92.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas BNTX's P/E ratio is -15.45. In terms of profitability, ACLX's ROE is -0.55%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ACLX and BNTX have similar daily volatility (0.00).Check BNTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, RPRX has a market cap of 22.9B. Regarding current trading prices, ACLX is priced at $115.07, while RPRX trades at $52.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas RPRX's P/E ratio is 28.03. In terms of profitability, ACLX's ROE is -0.55%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, ACLX and RPRX have similar daily volatility (0.00).Check RPRX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ROIV has a market cap of 20.9B. Regarding current trading prices, ACLX is priced at $115.07, while ROIV trades at $29.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ROIV's P/E ratio is -24.97. In terms of profitability, ACLX's ROE is -0.55%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ACLX and ROIV have similar daily volatility (0.00).Check ROIV's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ACLX is priced at $115.07, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ACLX's ROE is -0.55%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ACLX is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check BGNE's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, MRNA has a market cap of 20B. Regarding current trading prices, ACLX is priced at $115.07, while MRNA trades at $50.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas MRNA's P/E ratio is -6.19. In terms of profitability, ACLX's ROE is -0.55%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ACLX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check MRNA's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, INCY has a market cap of 19.7B. Regarding current trading prices, ACLX is priced at $115.07, while INCY trades at $99.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas INCY's P/E ratio is 13.96. In terms of profitability, ACLX's ROE is -0.55%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ACLX is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check INCY's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ACLX is priced at $115.07, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ACLX's ROE is -0.55%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ACLX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check DNA-WT's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, GMAB has a market cap of 16.3B. Regarding current trading prices, ACLX is priced at $115.07, while GMAB trades at $26.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas GMAB's P/E ratio is 20.27. In terms of profitability, ACLX's ROE is -0.55%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, ACLX and GMAB have similar daily volatility (0.00).Check GMAB's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ASND has a market cap of 15B. Regarding current trading prices, ACLX is priced at $115.07, while ASND trades at $244.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ASND's P/E ratio is 27.28. In terms of profitability, ACLX's ROE is -0.55%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ACLX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ASND's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, ACLX is priced at $115.07, while JAZZ trades at $232.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas JAZZ's P/E ratio is 2112.09. In terms of profitability, ACLX's ROE is -0.55%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ACLX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check JAZZ's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, SMMT has a market cap of 14.6B. Regarding current trading prices, ACLX is priced at $115.07, while SMMT trades at $18.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas SMMT's P/E ratio is -11.82. In terms of profitability, ACLX's ROE is -0.55%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ACLX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check SMMT's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, ACLX is priced at $115.07, while BBIO trades at $69.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas BBIO's P/E ratio is -18.34. In terms of profitability, ACLX's ROE is -0.55%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ACLX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check BBIO's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, ACLX is priced at $115.07, while EXEL trades at $51.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas EXEL's P/E ratio is 16.98. In terms of profitability, ACLX's ROE is -0.55%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ACLX is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check EXEL's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, IONS has a market cap of 12.8B. Regarding current trading prices, ACLX is priced at $115.07, while IONS trades at $79.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas IONS's P/E ratio is -38.61. In terms of profitability, ACLX's ROE is -0.55%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ACLX is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check IONS's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ACLX is priced at $115.07, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ACLX's ROE is -0.55%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ACLX is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check KRTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, ACLX is priced at $115.07, while AXSM trades at $235.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas AXSM's P/E ratio is -63.26. In terms of profitability, ACLX's ROE is -0.55%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ACLX is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check AXSM's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, MDGL has a market cap of 12B. Regarding current trading prices, ACLX is priced at $115.07, while MDGL trades at $522.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas MDGL's P/E ratio is -38.52. In terms of profitability, ACLX's ROE is -0.55%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ACLX and MDGL have similar daily volatility (0.00).Check MDGL's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ACLX is priced at $115.07, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ACLX's ROE is -0.55%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ACLX and RNAM have similar daily volatility (0.00).Check RNAM's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ARWR has a market cap of 11B. Regarding current trading prices, ACLX is priced at $115.07, while ARWR trades at $80.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ARWR's P/E ratio is -34.31. In terms of profitability, ACLX's ROE is -0.55%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ACLX and ARWR have similar daily volatility (0.00).Check ARWR's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, ACLX is priced at $115.07, while BMRN trades at $53.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas BMRN's P/E ratio is 38.53. In terms of profitability, ACLX's ROE is -0.55%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ACLX is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check BMRN's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ACLX is priced at $115.07, while CYTK trades at $77.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CYTK's P/E ratio is -11.27. In terms of profitability, ACLX's ROE is -0.55%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ACLX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CYTK's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ACLX is priced at $115.07, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ACLX's ROE is -0.55%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ACLX is less volatile compared to RXDX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check RXDX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, ACLX is priced at $115.07, while KRYS trades at $315.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas KRYS's P/E ratio is 41.79. In terms of profitability, ACLX's ROE is -0.55%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ACLX and KRYS have similar daily volatility (0.00).Check KRYS's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ACLX is priced at $115.07, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ACLX's ROE is -0.55%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ACLX is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check IMGN's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, ACLX is priced at $115.07, while IBRX trades at $8.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas IBRX's P/E ratio is -10.06. In terms of profitability, ACLX's ROE is -0.55%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ACLX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check IBRX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ACLX is priced at $115.07, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ACLX's ROE is -0.55%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ACLX and BPMC have similar daily volatility (0.00).Check BPMC's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, HALO has a market cap of 8.3B. Regarding current trading prices, ACLX is priced at $115.07, while HALO trades at $69.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas HALO's P/E ratio is 24.57. In terms of profitability, ACLX's ROE is -0.55%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ACLX and HALO have similar daily volatility (0.00).Check HALO's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ACLX is priced at $115.07, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CERE's P/E ratio is -16.47. In terms of profitability, ACLX's ROE is -0.55%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ACLX is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CERE's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, ACLX is priced at $115.07, while ABVX trades at $121.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ABVX's P/E ratio is -21.50. In terms of profitability, ACLX's ROE is -0.55%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, ACLX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ABVX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, ACLX is priced at $115.07, while PCVX trades at $54.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas PCVX's P/E ratio is -7.87. In terms of profitability, ACLX's ROE is -0.55%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ACLX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check PCVX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, ACLX is priced at $115.07, while NUVL trades at $105.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas NUVL's P/E ratio is -17.36. In terms of profitability, ACLX's ROE is -0.55%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ACLX is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check NUVL's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ACLX is priced at $115.07, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ACLX's ROE is -0.55%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ACLX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check MTSR's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, ACLX is priced at $115.07, while PRAX trades at $346.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas PRAX's P/E ratio is -25.87. In terms of profitability, ACLX's ROE is -0.55%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ACLX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check PRAX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, ACLX is priced at $115.07, while KYMR trades at $85.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas KYMR's P/E ratio is -23.91. In terms of profitability, ACLX's ROE is -0.55%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ACLX and KYMR have similar daily volatility (0.00).Check KYMR's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, TECH has a market cap of 7B. Regarding current trading prices, ACLX is priced at $115.07, while TECH trades at $45.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas TECH's P/E ratio is 64.13. In terms of profitability, ACLX's ROE is -0.55%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ACLX and TECH have similar daily volatility (0.00).Check TECH's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ACLX is priced at $115.07, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ACLX's ROE is -0.55%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ACLX and MRUS have similar daily volatility (0.00).Check MRUS's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, ACLX is priced at $115.07, while PTGX trades at $104.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas PTGX's P/E ratio is -57.39. In terms of profitability, ACLX's ROE is -0.55%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ACLX and PTGX have similar daily volatility (0.00).Check PTGX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ACLX is priced at $115.07, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas RETA's P/E ratio is -66.29. In terms of profitability, ACLX's ROE is -0.55%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ACLX is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check RETA's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, TGTX has a market cap of 6.5B. Regarding current trading prices, ACLX is priced at $115.07, while TGTX trades at $42.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas TGTX's P/E ratio is 14.91. In terms of profitability, ACLX's ROE is -0.55%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ACLX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check TGTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, ACLX is priced at $115.07, while CGON trades at $74.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CGON's P/E ratio is -31.62. In terms of profitability, ACLX's ROE is -0.55%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ACLX is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CGON's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ALKS has a market cap of 6.5B. Regarding current trading prices, ACLX is priced at $115.07, while ALKS trades at $38.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ALKS's P/E ratio is 43.23. In terms of profitability, ACLX's ROE is -0.55%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ACLX and ALKS have similar daily volatility (0.00).Check ALKS's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, ACLX is priced at $115.07, while RYTM trades at $94.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas RYTM's P/E ratio is -29.94. In terms of profitability, ACLX's ROE is -0.55%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ACLX and RYTM have similar daily volatility (0.00).Check RYTM's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, ACLX is priced at $115.07, while BLTE trades at $153.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas BLTE's P/E ratio is -66.75. In terms of profitability, ACLX's ROE is -0.55%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, ACLX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check BLTE's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CORT has a market cap of 6.1B. Regarding current trading prices, ACLX is priced at $115.07, while CORT trades at $57.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CORT's P/E ratio is 163.09. In terms of profitability, ACLX's ROE is -0.55%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ACLX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CORT's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, ACLX is priced at $115.07, while CNTA trades at $39.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CNTA's P/E ratio is -22.24. In terms of profitability, ACLX's ROE is -0.55%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ACLX is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CNTA's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, ACLX is priced at $115.07, while PTCT trades at $73.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas PTCT's P/E ratio is -28.92. In terms of profitability, ACLX's ROE is -0.55%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ACLX is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check PTCT's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, ACLX is priced at $115.07, while CELC trades at $124.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CELC's P/E ratio is -32.84. In terms of profitability, ACLX's ROE is -0.55%, compared to CELC's ROE of -2.03%. Regarding short-term risk, ACLX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CELC's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, SRRK has a market cap of 6B. Regarding current trading prices, ACLX is priced at $115.07, while SRRK trades at $50.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas SRRK's P/E ratio is -14.54. In terms of profitability, ACLX's ROE is -0.55%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ACLX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check SRRK's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, IMVT has a market cap of 6B. Regarding current trading prices, ACLX is priced at $115.07, while IMVT trades at $28.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas IMVT's P/E ratio is -10.96. In terms of profitability, ACLX's ROE is -0.55%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ACLX and IMVT have similar daily volatility (0.00).Check IMVT's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ACLX is priced at $115.07, while COGT trades at $34.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas COGT's P/E ratio is -15.80. In terms of profitability, ACLX's ROE is -0.55%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ACLX is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check COGT's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ACLX is priced at $115.07, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ACLX's ROE is -0.55%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ACLX and CDTX have similar daily volatility (0.00).Check CDTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ACLX is priced at $115.07, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ACLX's ROE is -0.55%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ACLX is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ABCM's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ACLX is priced at $115.07, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ACLX's ROE is -0.55%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ACLX is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ISEE's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, ACLX is priced at $115.07, while MIRM trades at $109.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas MIRM's P/E ratio is -8.03. In terms of profitability, ACLX's ROE is -0.55%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ACLX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check MIRM's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, ACLX is priced at $115.07, while LEGN trades at $28.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas LEGN's P/E ratio is -20.78. In terms of profitability, ACLX's ROE is -0.55%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, ACLX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check LEGN's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ACLX is priced at $115.07, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas APLS's P/E ratio is 38.35. In terms of profitability, ACLX's ROE is -0.55%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ACLX is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check APLS's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, APGE has a market cap of 5.2B. Regarding current trading prices, ACLX is priced at $115.07, while APGE trades at $83.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas APGE's P/E ratio is -19.39. In terms of profitability, ACLX's ROE is -0.55%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ACLX and APGE have similar daily volatility (0.00).Check APGE's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ACLX is priced at $115.07, while FBIOX trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ACLX's ROE is -0.55%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ACLX and FBIOX have similar daily volatility (0.00).Check FBIOX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, LQDA has a market cap of 5.1B. Regarding current trading prices, ACLX is priced at $115.07, while LQDA trades at $57.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas LQDA's P/E ratio is 338.76. In terms of profitability, ACLX's ROE is -0.55%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ACLX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check LQDA's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, ACLX is priced at $115.07, while CRSP trades at $52.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CRSP's P/E ratio is -8.55. In terms of profitability, ACLX's ROE is -0.55%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ACLX and CRSP have similar daily volatility (0.00).Check CRSP's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ACLX is priced at $115.07, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas TERN's P/E ratio is -51.41. In terms of profitability, ACLX's ROE is -0.55%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ACLX and TERN have similar daily volatility (0.00).Check TERN's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, SYRE has a market cap of 4.6B. Regarding current trading prices, ACLX is priced at $115.07, while SYRE trades at $77.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas SYRE's P/E ratio is -36.00. In terms of profitability, ACLX's ROE is -0.55%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ACLX is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check SYRE's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ACLX is priced at $115.07, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ACLX's ROE is -0.55%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ACLX and FOLD have similar daily volatility (0.00).Check FOLD's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ACLX is priced at $115.07, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ACLX's ROE is -0.55%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ACLX is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check AKRO's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ACLX is priced at $115.07, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ACLX's ROE is -0.55%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ACLX is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ALPN's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, KNSA has a market cap of 4.4B. Regarding current trading prices, ACLX is priced at $115.07, while KNSA trades at $59.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas KNSA's P/E ratio is 64.97. In terms of profitability, ACLX's ROE is -0.55%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ACLX and KNSA have similar daily volatility (0.00).Check KNSA's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, ACLX is priced at $115.07, while LGND trades at $220.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas LGND's P/E ratio is 28.88. In terms of profitability, ACLX's ROE is -0.55%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ACLX and LGND have similar daily volatility (0.00).Check LGND's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, NAMS has a market cap of 4.4B. Regarding current trading prices, ACLX is priced at $115.07, while NAMS trades at $37.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas NAMS's P/E ratio is -21.21. In terms of profitability, ACLX's ROE is -0.55%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ACLX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check NAMS's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, ACLX is priced at $115.07, while XENE trades at $56.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas XENE's P/E ratio is -11.89. In terms of profitability, ACLX's ROE is -0.55%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ACLX and XENE have similar daily volatility (0.00).Check XENE's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, ACLX is priced at $115.07, while MANE trades at $108.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas MANE's P/E ratio is -44.85. In terms of profitability, ACLX's ROE is -0.55%, compared to MANE's ROE of -0.76%. Regarding short-term risk, ACLX and MANE have similar daily volatility (0.00).Check MANE's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ACLX is priced at $115.07, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas OPT's P/E ratio is -1.52. In terms of profitability, ACLX's ROE is -0.55%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ACLX and OPT have similar daily volatility (0.00).Check OPT's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CAI has a market cap of 4.2B. Regarding current trading prices, ACLX is priced at $115.07, while CAI trades at $14.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CAI's P/E ratio is -5.32. In terms of profitability, ACLX's ROE is -0.55%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ACLX and CAI have similar daily volatility (0.00).Check CAI's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, TVTX has a market cap of 4.1B. Regarding current trading prices, ACLX is priced at $115.07, while TVTX trades at $44.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas TVTX's P/E ratio is -89.10. In terms of profitability, ACLX's ROE is -0.55%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ACLX is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check TVTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ACLX is priced at $115.07, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ACLX's ROE is -0.55%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ACLX is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check MRTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CRNX has a market cap of 4B. Regarding current trading prices, ACLX is priced at $115.07, while CRNX trades at $37.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CRNX's P/E ratio is -7.29. In terms of profitability, ACLX's ROE is -0.55%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ACLX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CRNX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, ACLX is priced at $115.07, while CPRX trades at $31.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CPRX's P/E ratio is 18.01. In terms of profitability, ACLX's ROE is -0.55%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ACLX is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CPRX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, ACLX is priced at $115.07, while ACAD trades at $22.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ACAD's P/E ratio is 10.04. In terms of profitability, ACLX's ROE is -0.55%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ACLX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ACAD's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ACLX is priced at $115.07, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ACLX's ROE is -0.55%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ACLX is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check RYZB's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ACLX is priced at $115.07, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ACLX's ROE is -0.55%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ACLX is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check CBAY's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ACLX is priced at $115.07, while VKTX trades at $31.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas VKTX's P/E ratio is -7.64. In terms of profitability, ACLX's ROE is -0.55%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ACLX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check VKTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, ACLX is priced at $115.07, while EWTX trades at $33.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas EWTX's P/E ratio is -20.34. In terms of profitability, ACLX's ROE is -0.55%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ACLX is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check EWTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, ACLX is priced at $115.07, while DNTH trades at $85.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas DNTH's P/E ratio is -20.27. In terms of profitability, ACLX's ROE is -0.55%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ACLX and DNTH have similar daily volatility (0.00).Check DNTH's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, ACLX is priced at $115.07, while TLX trades at $10.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas TLX's P/E ratio is -526.00. In terms of profitability, ACLX's ROE is -0.55%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ACLX and TLX have similar daily volatility (0.00).Check TLX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ACLX is priced at $115.07, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ACLX's ROE is -0.55%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ACLX and SWTX have similar daily volatility (0.00).Check SWTX's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, BEAM has a market cap of 3.3B. Regarding current trading prices, ACLX is priced at $115.07, while BEAM trades at $31.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas BEAM's P/E ratio is -65.00. In terms of profitability, ACLX's ROE is -0.55%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, ACLX and BEAM have similar daily volatility (0.00).Check BEAM's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ERAS has a market cap of 3.3B. Regarding current trading prices, ACLX is priced at $115.07, while ERAS trades at $10.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ERAS's P/E ratio is -11.25. In terms of profitability, ACLX's ROE is -0.55%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ACLX and ERAS have similar daily volatility (0.00).Check ERAS's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, ACLX is priced at $115.07, while DNLI trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas DNLI's P/E ratio is -6.88. In terms of profitability, ACLX's ROE is -0.55%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ACLX is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check DNLI's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, NAMSW has a market cap of 3.1B. Regarding current trading prices, ACLX is priced at $115.07, while NAMSW trades at $27.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas NAMSW's P/E ratio is N/A. In terms of profitability, ACLX's ROE is -0.55%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ACLX is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check NAMSW's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, ACLX is priced at $115.07, while ALMS trades at $24.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas ALMS's P/E ratio is -8.69. In terms of profitability, ACLX's ROE is -0.55%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, ACLX is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for ACLX.Check ALMS's competition here

ACLX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACLX stands at 6.7B. In comparison, VCYT has a market cap of 3.1B. Regarding current trading prices, ACLX is priced at $115.07, while VCYT trades at $38.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACLX currently has a P/E ratio of -28.27, whereas VCYT's P/E ratio is 35.42. In terms of profitability, ACLX's ROE is -0.55%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, ACLX and VCYT have similar daily volatility (0.00).Check VCYT's competition here